227 related articles for article (PubMed ID: 19637953)
1. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.
O'Connor TL; Kossoff E
Pharmacotherapy; 2009 Aug; 29(8):993-6. PubMed ID: 19637953
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-induced nail changes: possible role of its vehicle (Cremophor EL).
Minutilli E; Izzo F; Natoli G; Psaila A; Di Filippo F; Terzoli E
Eur J Dermatol; 2006; 16(6):693-4. PubMed ID: 17229616
[No Abstract] [Full Text] [Related]
3. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
[TBL] [Abstract][Full Text] [Related]
4. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
[TBL] [Abstract][Full Text] [Related]
5. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
Bardelmeijer HA; Ouwehand M; Malingré MM; Schellens J; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2002 Feb; 49(2):119-25. PubMed ID: 11862425
[TBL] [Abstract][Full Text] [Related]
6. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation.
Zhang JA; Anyarambhatla G; Ma L; Ugwu S; Xuan T; Sardone T; Ahmad I
Eur J Pharm Biopharm; 2005 Jan; 59(1):177-87. PubMed ID: 15567316
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of liposomal paclitaxel against MCF-7 breast cancer cells.
Heney M; Alipour M; Vergidis D; Omri A; Mugabe C; Th'ng J; Suntres Z
Can J Physiol Pharmacol; 2010 Dec; 88(12):1172-80. PubMed ID: 21164564
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
Horiguchi J; Rai Y; Tamura K; Taki T; Hisamatsu K; Ito Y; Seriu T; Tajima T
Anticancer Res; 2009 Feb; 29(2):625-30. PubMed ID: 19331212
[TBL] [Abstract][Full Text] [Related]
10. Adverse effects of paclitaxel in patients with alcohol abuse histories.
Henderson-Martin B
Clin J Oncol Nurs; 2000; 4(1):11-4. PubMed ID: 10865578
[TBL] [Abstract][Full Text] [Related]
11. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin.
Decorti G; Bartoli Klugmann F; Candussio L; Baldini L
Anticancer Res; 1996; 16(1):317-20. PubMed ID: 8615628
[TBL] [Abstract][Full Text] [Related]
12. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
van Tellingen O; Huizing MT; Panday VR; Schellens JH; Nooijen WJ; Beijnen JH
Br J Cancer; 1999 Sep; 81(2):330-5. PubMed ID: 10496361
[TBL] [Abstract][Full Text] [Related]
13. A rare case of generalized tonic-clonic seizure related to paclitaxel infusion.
Ajiboye O; Renu N; Ezegwu O; Vohra I; Ayub MT
J Clin Pharm Ther; 2019 Dec; 44(6):974-976. PubMed ID: 31423611
[TBL] [Abstract][Full Text] [Related]
14. Protein nanoparticles as drug carriers in clinical medicine.
Hawkins MJ; Soon-Shiong P; Desai N
Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
[TBL] [Abstract][Full Text] [Related]
15. Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.
Brouwer E; Verweij J; Hauns B; Loos WJ; Nooter K; Mross K; Stoter G; Sparreboom A
Anal Biochem; 1998 Aug; 261(2):198-202. PubMed ID: 9716422
[TBL] [Abstract][Full Text] [Related]
16. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study.
Pires LA; Hegg R; Valduga CJ; Graziani SR; Rodrigues DG; Maranhão RC
Cancer Chemother Pharmacol; 2009 Jan; 63(2):281-7. PubMed ID: 18365196
[TBL] [Abstract][Full Text] [Related]
17. Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL).
De Giorgi U; Rosti G; Monti M; Frassineti GL; Marangolo M
Ann Oncol; 2003 Oct; 14(10):1588-9. PubMed ID: 14504063
[No Abstract] [Full Text] [Related]
18. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1035-48. PubMed ID: 18791717
[TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
Henderson IC; Bhatia V
Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
[TBL] [Abstract][Full Text] [Related]
20. [Safety evaluation of paclitaxel injection NK in adjuvant therapy for breast cancer].
Takahara S; Yamamoto H; Tokushima Y; Shiba E
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1851-6. PubMed ID: 19920387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]